Advertisement
Dr. Lyne Gagnon, ProMetic's Director R&D, Biology, presented data onPBI-1402 in a poster entitled "PBI-1402 increases hemoglobin level and redblood cell count in chemotherapy-induced anemia". Results demonstrated that aonce daily oral treatment of PBI-1402 induces a significant increase inhemoglobin ("Hb") level, red blood cell ("RBC") count and hematocrit ("Ht") inCIA patients. Furthermore, results suggest that PBI-1402 can reduce the needfor RBC transfusion, since only 6% of patients in the clinical trial requiredtransfusion.
Advertisement
"Subsequent positive data compiled from the 28 patients having completedthe PBI-1402 CIA clinical trial include the fact that 26 of these patients didnot require RBC transfusions while maintaining their full chemotherapyregimen. This data further supports that PBI-1402's current performance is inline with the Food and Drug Administration's ("FDA") recommendation ofreducing patient need for RBC transfusions," states Mr. Pierre Laurin,ProMetic's President and Chief Executive Officer. "Additionally, PBI-1402offers the added advantage of oral dosing which allows for a convenientmanagement of anemia without interference with other treatments received bythe CIA patients."
In the March 13, 2008 briefing document, the FDA's Oncologic DrugsAdvisory Committee emphasized that the primary objective of treating CIApatients with erythropoiesis-stimulating agents ("ESAs") as being the abilityto reduce the need for RBC transfusions. Approximately 50% of anemic patientsreceiving chemotherapy require RBC transfusions, and 20%-25% of patientstreated with ESAs still require RBC transfusions.
About ProMetic Life Sciences Inc.
ProMetic Life Sciences Inc. ("ProMetic") (www.prometic.com) is abiopharmaceutical company specialized in the research, development,manufacture and marketing of a variety of commercial applications derived fromits proprietary Mimetic Ligand(TM) technology. This technology is used inlarge-scale purification of biologics and the elimination of pathogens.ProMetic is also active in therapeutic drug development with the mission tobring to market effective, innovative, lower cost, less toxic products for thetreatment of hematology and cancer. Its drug discovery platform is focused onreplacing complex, expensive proteins with synthetic "drug-like" proteinmimetics. Headquartered in Montreal (Canada), ProMetic has R&D facilities inthe U.K., the U.S. and Canada, manufacturing facilities in the U.K. andbusiness development activities in the US, Europe, Asia and in theMiddle-East.
Forward Looking Statements
This press release contains forward-looking statements about ProMetic'sobjectives, strategies and businesses that involve risks and uncertainties.These statements are "forward-looking" because they are based on our currentexpectations about the markets we operate in and on various estimates andassumptions. Actual events or results may differ materially from thoseanticipated in these forward-looking statements if known or unknown risksaffect our business, or if our estimates or assumptions turn out to beinaccurate. Such risks and assumptions include, but are not limited to,ProMetic's ability to develop, manufacture, and successfully commercializevalue-added pharmaceutical products, the availability of funds and resourcesto pursue R&D projects, the successful and timely completion of clinicalstudies, the ability of ProMetic to take advantage of business opportunitiesin the pharmaceutical industry, uncertainties related to the regulatoryprocess and general changes in economic con
